- The Wall Street Journal•2 hours ago
European central banks are looking to corporate debt to help get the region’s economy firing on all cylinders again, but many companies are wary of investing the proceeds from those purchases.
- Zacks•17 hours ago
Regeneron (REGN) and partner Sanofi's atopic dermatitis treatment, dupilumab, is under priority review in the U.S. A response should be out by Mar 29, 2017.
- Reuters•20 hours ago
Sanofi SA said on Monday the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development of a Zika vaccine, as efforts to prevent the infection gather momentum. The funding from the HHS' Biomedical Advanced Research and Development Authority (BARDA) will be used for mid-stage trials, expected to begin in the first half of 2018, and for manufacturing, the French drugmaker said. Work on the vaccine began in March as a collaborative effort between the U.S. Department Of Defense's Walter Reed Army Institute of Research (WRAIR), BARDA and the National Institutes of Health.
Paris - Paris Delayed Price. Currency in EUR
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||67.42 - 68.61|
|52wk Range||24.83 - 93.82|
|1y Target Est||N/A|
|P/E Ratio (ttm)||20.98|
|Avg Vol (3m)||9,729|
|Dividend & Yield||N/A (N/A)|